Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update

Figure 1

Incidence of neoplasms (benign or malignant) in randomized trials of everolimus within a CNI-free or low-CNI regimen. CNI, calcineurin inhibitor [38–45].